MedPath

Immunmodulation in Patients With HHT

Completed
Conditions
Hereditary Haemorrhagic Telangiectasia (HHT)
Interventions
Other: blood sample
Registration Number
NCT02983253
Lead Sponsor
University Hospital, Essen
Brief Summary

Hereditary haemorrhagic telangiectasia (HHT), also known as Rendu-Osler-Weber syndrome, is an inherited multisystemic disorder. Literature suggests that HHT is often associated with higher frequency of infectious diseases.

The purpose of this study is to evaluate a variety of immunologic parameters in the blood serum of HHT patients in comparison to probands.

Detailed Description

Hereditary haemorrhagic telangiectasia (HHT), also known as Rendu-Osler-Weber syndrome, is an inherited multisystemic disorder with recurrent epistaxis, mucocutaneous telangiectasia and visceral arteriovenous malformations. Literature and the investigators' observation suggest that HHT is often associated with higher frequency of infectious diseases. This might be a hint for a immunocompromised situation.

The purpose of this study is to evaluate a variety of immunologic parameters in the blood serum of HHT patients in comparison to probands.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
124
Inclusion Criteria
  • aged 18 or over, HHT
Exclusion Criteria
  • Unable to provide informed consent

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Patients with HHTblood sampleblood sample of patients with HHT
probandsblood sampleblood sample of healthy controls
Primary Outcome Measures
NameTimeMethod
Amounts of leucocytes in patients with HHTNovember 2016 - December 2018
Secondary Outcome Measures
NameTimeMethod
Differences in distribution of leucocytes in patients with HHTNovember 2016 - December 2018

Trial Locations

Locations (1)

University Hospital Essen

🇩🇪

Essen, Germany

© Copyright 2025. All Rights Reserved by MedPath